Dutch Minister Demands ‘Socially Acceptable’ Price For Gilead’s Trodelvy
Executive Summary
Gilead’s breast cancer drug Trodelvy is too expensive for the benefits it offers and will not be reimbursed in the Netherlands unless the company drops its price, said the Dutch health minister.